| Title | Blood lipids in patients suffering from colorectal cancer | |
| Authors | Erasmia Singelaki, Nikolaos Nikiteas and Andreas Manouras
First Department of Propaedeutic Surgery, Hippokrateion Hospital, Athens Medical School, University of Athens, Hellas |
|
| Citation | Singelaki, E., Nikiteas, N., Manouras, A.: Blood lipids in patients suffering from colorectal cancer, Epitheorese Klin. Farmakol. Farmakokinet. 27(1): 33-38 (2013) | |
| Publication Date | Accepted for publication (Final Version): April 10, 2013 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Colorectal cancer, blood lipids, patients. | |
| Other Terms | review article | |
| Summary | INTRODUCTION: The cause of cancer of the large intestine is unknown. Predispositional factors have been implicated related to concurrent large intestine diseases such as polyposis, ulcerous colitis, Crohn’s disease and infection of Epstein Bar Virus, while in the past fifteen-year period there has been discussion on the relation between lipids and the presence of colorectal cancer. MATERIAL: The study of this issue took into consideration the lipoprotein electrophoresis data of 162 colorectal cancer patients and 67 healthy subjects. The cancer patients comprised of 88 males and 74 females while the healthy subjects were 37 men and 30 women. RESULTS: The average HDL value of the patients was higher (51.00 mg/dl) as opposed to that of the healthy subjects (28.13 mg/dl). The average beta value of the patients was 47.1% compared to 53.32% of the healthy subjects. The average pre-beta value was greater (23.63%) than the respective value for healthy subjects (17.95%). The average Lp(a) of the patients was 33.67% compared to 0.84% of the healthy subjection. CONCLUSION: Therefore lipoprotein electrophoresis is an examination that may be used for the control of patients suspected of cancer in the large intestine. | |
| References | 1. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H., Joslyn G., Stevens J., Spirio L., Robertson M., et al.: Identification and characterization of the familiar adenomatous polyposis coli gene. Cell 66: 589-600 (1991)
2. Coussens L.M., Werb Z.: Inflammation and cancer. Nature 420(6917): 860-867 (2002) 3. Devroede G.J., Taylor W.F., Sauer W.G., et al.: Cancer risk and life expectancy of children with ulcerative colitis. N. Engl. J. Med. 285: 17-21 (1979) 4. Erlinger T.P., Platz E.A., Rifai N., et al.: C-reactive protein and the risk of incident colorectal cancer. JAMA 291: 585-590 (2004) 5. Il’yasova D., Colbert L.H., Harris T.B., Newman A.B., Bauer D.C., Satterfield S., Kritchevsky S.B: Circulating levels of inflammantory markers and cancer. Cancer Epidemiol. Biomarkers Prev. 14: 2413-2418 (2005) 6. Zhang S.M., Buring J.E., Lee I.M., et al.: C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann. Intern. Med. 142: 425-432 (2005) 7. Gunter M.J., Stolzenberg-Solomon R., Cross A.J., et al.: A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 66: 2483-2487 (2006) 8. Siemens C., Visser L.E., Coebergh J.W., et al.: Creactive protein levels, variation in the C-reactive protein gene, and cancer risk: Rotterdam Study. J. Clin. Oncol. 24: 5216-5222 (2006) 9. Trichopoulos D., Psaltopoulou T., Orfanos P., et al.: Plasma C reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol. Biomarkers Prev. 15: 381-384 (2006) 10. Allin K.H., Bojesen S.E., Nordestgaard B.G.: Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J. Clin. Oncol. 27: 2217-2224 (2009) 11. Tsilidis K.K., Branchini C., Guallar E., et al.: C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int. J. Cancer 23: 1133-1140 (2008) 12. Yudkin J.S., Stehouwer C.D., Emeis J.J., Coppack S.W.: C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunctions: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 19: 972-978 (1999) 13. Festa A., D’Agostino R.,Jr, Howard G., et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42-47 (2000) 14. Pischon T., Lahman P.H., Boeing H., et al.: Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 98: 920-931 (2006) 15. Giovannicci E.: Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am. J. Clin. Nitr. 86(Suppl. 3): S836-S842 (2007) 16. Jess T., Gamborg M., Matzen P., et al.: Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population based cohort studies. Am. J. Gastroenterol. 100: 2724-2729 (2005) 17. Canavan C., Abrams K.R., Mayberry J.: Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Alimentary Pharmacol Ther. 23: 1097-1104 (2006) 18. Zhang C.Q., Zhang Y., Pan Z.Z., Liao W.T., Li M.Z., Zeng M.S.: Infection of Epstein-Barr virus in colorectal cancer in Chinese. Ai Zheng. 25: 1356-1360 (2006) 19. Gaard M., Tretli S., Urdal P.: Blood lipid and lipoprotein levels and the risk of cancer of the colon and rectum a prospective study of 62,173 Norwegian men and women. Scand. J. Gastroenterol. 32: 162-168 (1997) 20. Schwartz’s: Principles of Surgery, 9th Edition, McGraw-Hill, 2009 21. Pisiotis C.A., Gulessenan H.P., Condon R.E.: Colorectal carcinoma in the first twenty-five years of life. J. Surg. Oncol. 6(1): 87-91 (1974) 22. Nigri N.D., Campbell R.L.: Bile and Intestinal Cancer in the Bile Acids. 23. Nattenberg L.W: Study of polycyclic hydrocarbon hydroxylases of the intestine possibly related to cancer: Effect of diet on benzpyrene hydroxylase activity. Cancer 28(1): 99-102 (1971) 24. Burkitt D.P.: Epidemiology of cancer of the colon and rectum. Cancer 28(1): 3-13 (1971) 25. Hill M.J., Drasear B.S., Hawksworth C.: Bacteria and aetiology of cancer of large bowel. Lancet 1(7690): 95-100 (1971) 26. Correc P., Kostner G.M., Burtin P.: A comparative study of the localization of plasminogen and apolipoprotein (A) in human carcinomas. Thromb. Res. 58: 213-220 (1990) 27. Fredrickson D.S., Lees R.S.: A system for phenotyping hyperhipidemias. Circulation 31: 321-323 (1965) 28. Williams S.T., Beart R.W.: Staging of colorectal cancer. Semin. Surg. Oncol. 8: 89-93 (1992). 29. Cowan L.D., O’Connell D.L., Criqui M.H., Barret-Connor E., Bush T.L., Wallace R.B.: Cancer mortality and lipid and lipoprotein levels. The lipid research clinics program mortality follow-up study. Am. J. Epidemiol. 131: 468-482 (1990) 30. Chirkin K., Saparov D.: The changes of the transfer of lipids in the blood serum in patients with colon cancer. Department of Oncology and Biochemistry, Department at the Bitevski Medical Institute. Edition July 10, 1987. Republished 1990 |
|
| Relative Papers |
Online ISSN 1011-6575